Is PT-141 (Bremelanotide) Legal in New York?
HealthRX.com
Vyleesi is the approved form; PT vials are not
Key numbers
- 45 minutesMinimum time before anticipated sexual activity to inject the 1.75 mg Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 doses per monthUsage ceiling: the Vyleesi label says more than 8 doses per month is not recommendedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Vyleesi-treated patients with nausea, the most common side effect (placebo 1.3%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- FDA status / Approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
- Form / 1.75 mg subcutaneous autoinjector; prescription only [1]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Not indicated for / Men, postmenopausal women, or enhancing sexual performance [1]
- 'PT-141' research or compounded products / Not Vyleesi; not FDA-approved drugs [3][1]
- FDA bulk-substance lists / Bremelanotide appears in no category [4][5]
- HHS October 2026 peptide policy / Not one of the six peptides covered [6]
- Boxed warning or REMS / None in the label or the 2019 approval letter [1][2]
The federal answer
Vyleesi is the FDA-approved bremelanotide product, approved on June 21, 2019 under NDA 210557, now held by Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector, prescription only [1].
The approved use is premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance [1].
Questions worth asking
Are the products sold as 'PT-141' the same as Vyleesi?
No. Vials, powders and compounded injections marketed as PT-141 are not Vyleesi and are not FDA-approved drugs [1][3]. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [3].
Bremelanotide does not appear on FDA's page of bulk substances that may present significant safety risks (content dated April 22, 2026), and it appears in no category on FDA's bulk-substance lists [4][5]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6].
What the Vyleesi label says
The label says the dose is 1.75 mg under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. It says not to give more than one dose within 24 hours and that more than 8 doses per month is not recommended [1].
Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease [1]. Each dose produces a transient rise in blood pressure and a fall in heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down by up to 5 beats per minute and values usually back to baseline within 12 hours [1]. Those are maximal, not average, figures. In a separate ambulatory study of 127 premenopausal women dosed once daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4) [1].
Nausea is the most common adverse reaction, reported by 40.0% of Vyleesi-treated patients versus 1.3% on placebo in the pooled phase 3 trials, with 13% needing anti-nausea medicine and 8% stopping the trials because of it [1]. The label also notes focal hyperpigmentation, including on the face, gums and breasts, reported by 1% of patients who received up to 8 doses a month versus none on placebo [1].
Frequently asked questions
Is PT-141 legal in New York?
Is PT-141 the same as Vyleesi?
Is compounded bremelanotide an FDA-approved drug?
Who is Vyleesi approved for?
Does Vyleesi have a boxed warning or a REMS?
What side effects does the label list?
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.